Beijing Tide Pharmaceutical Co., Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-31
RECRUITING4
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| TCC1727 tablet(1) NCT05970016 |
P1/2 | Recruiting | Patients with Advanced Solid Tumors | 56 | 2025-07-30 |
| TRD205 tablets NCT07121101 |
P2 | Not yet recruiting | Postoperative Analgesia After Unilateral Hip Arthroplasty | 40 | 2025-11-20 |
| TDI01 suspension NCT06169722 |
P1/2 | Active, not recruiting | GVHD, Chronic | 60 | 2026-02 (+13 mo) |
| TRD205 NCT07123402 |
P2 | Enrolling by invitation | Chronic Postoperative Neuralgia | 184 | 2026-04-20 |
| TRD205 NCT07543796 |
P2 | Recruiting | Postoperative Analgesia After Unilateral Hip Arthroplasty | 200 | 2026-06-27 |
| TCC1727 tablet 90mg NCT07371663 |
P1/2 | Recruiting | Solid Cancers; NSCLC (Advanced Non-small Cell Lung Cancer) | 266 | 2028-09-30 |
| TDI01 NCT07464912 |
P3 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 508 | 2029-07-30 |